Tanshinones

Compound Class	Tanshinones — lipophilic abietane-type diterpene quinones; the fat-soluble fraction of danshen
Representative Members	Tanshinone IIA (most studied), tanshinone I, cryptotanshinone, dihydrotanshinone I
Botanical Sources	Salvia miltiorrhiza (danshen; red sage)
Plant Part(s)	Root and rhizome
Typical Standardisation	Total tanshinones or tanshinone IIA by HPLC; 5–10% common commercial range
Primary Applications	Cardiovascular-support formulation, antioxidant and anti-fibrotic positioning, microcirculation support
Claim Strength (Overview)	Moderate — extensive mechanistic and Chinese clinical use; Western-standard RCT evidence remains limited
Buy from Herbuno	Tanshinones 10% Powder (Danshen Extract) | Standardized Salvia miltiorrhiza → Tanshinones 5% Powder (Danshen Extract) | Standardized Salvia miltiorrhiza →

Name origin: Tanshinone is derived from danshen, the Chinese name for the source plant (丹参, literally "red ginseng," referring to the root’s distinctive brick-red colour rather than any relation to true Panax ginseng), combined with the "-one" suffix denoting the quinone functional group that gives the compounds their characteristic colour and redox chemistry. Traditional use: Danshen is one of the most heavily used single herbs in Traditional Chinese Medicine, classified as a blood-invigorating (huo xue) and stasis-dispersing agent, prescribed for centuries for chest pain, palpitations, menstrual disorders, and conditions understood in TCM terms as blood stagnation — a traditional indication set that maps with unusual directness onto the modern cardiovascular applications for which danshen preparations are now clinically used across China and neighbouring countries. Research trajectory: Danshen has been the subject of enormous research investment within China, where danshen injection preparations, dropping pills, and combination formulas are in routine clinical use for angina, myocardial infarction, and cerebrovascular conditions; the resulting evidence base is extensive but has been slower to gain acceptance under Western trial-methodology standards, creating a genuine East–West evidentiary asymmetry that formulators should understand when scoping claims for regulated Western markets. Commercial source: Salvia miltiorrhiza root extract standardized to total tanshinone or tanshinone IIA content is the commercial format for the lipophilic fraction; note that danshen also contains a separate, water-soluble phenolic-acid fraction (salvianolic acids) that is not captured by tanshinone standardization.

---

Evidence for Tanshinones Applications

Tanshinone IIA is the most extensively characterized member of this class and has a well-developed cardiovascular mechanism. A review of its cardiovascular actions found that emerging experimental studies and clinical trials demonstrate tanshinone IIA prevents atherogenesis as well as cardiac injury and hypertrophy, acting in atherosclerosis by inhibiting LDL oxidation, monocyte adhesion to endothelium, smooth muscle cell migration and proliferation, macrophage cholesterol accumulation, pro-inflammatory cytokine expression, and platelet aggregation (Gao 2012). This is a genuinely multi-target anti-atherosclerotic mechanism rather than a single-pathway effect, and the compound has been clinically used in Asian countries for prevention and treatment of coronary heart disease. Claim strength: Moderate.

More recent mechanistic work has focused on tanshinone IIA’s activity against endothelial dysfunction, the initiating event in most vascular disease, finding that beyond its antioxidative activity the compound inhibits inflammatory signalling via the TLR4-NF-κB axis and the MAPK pathway, and blocks pro-fibrotic components including TGF-βR1 and AT1R along with the Wnt, Notch, and ET-1 signalling pathways (Oxid Med Cell Longev 2022). The anti-fibrotic dimension is distinct from the anti-atherosclerotic activity above and represents a separate potential application area for this compound class. Claim strength: Moderate (mechanistic).

A critical compositional point that formulators frequently miss: danshen’s pharmacological activity derives from two chemically distinct fractions acting in apparent synergy. The lipophilic tanshinones (tanshinone I, tanshinone IIA, cryptotanshinone, dihydrotanshinone) documented on this page are only half the picture; the hydrophilic fraction — salvianolic acid A and B, danshensu, protocatechuic aldehyde — contributes substantially to the herb’s cardiovascular protection and is not captured by a tanshinone-percentage standardization. An ethanol-extracted, tanshinone-standardized product and a water-extracted, salvianolic-acid-rich product are meaningfully different ingredients from the same root. Claim strength: Moderate.

Vasodilatory and antihypertensive activity has been demonstrated in animal models, with tanshinone IIA producing concentration-dependent relaxation in isolated aortic rings and lowering systolic blood pressure in spontaneously hypertensive rats but notably not in normotensive controls — a selectivity that is mechanistically interesting (suggesting the effect engages only in a dysregulated system) but which remains animal-model data rather than human evidence. Formulators should not translate this into a blood-pressure claim without human substantiation. Claim strength: Emerging.

The evidentiary asymmetry deserves candid statement: danshen preparations are in extensive routine clinical use across China with a correspondingly large body of Chinese-language clinical literature, but this evidence base has been less rigorously validated under the trial-design standards typically required in Western regulatory contexts, and high-quality independent Western RCT data for tanshinone-standardized oral supplements specifically remains limited. Formulators marketing into Western regulated markets should scope claims to the mechanistic and traditional-use evidence rather than implying Western-standard clinical validation. Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries danshen root extract standardized to 10% and 5% total tanshinones by HPLC. Buyers should be explicit about whether their formulation objective requires the lipophilic tanshinone fraction (captured by these grades) or the hydrophilic salvianolic-acid fraction (not captured), as these require different extraction solvents and deliver mechanistically distinct constituent profiles from the same root material.

Dosing guidance for tanshinone-standardized oral extracts is less well established in the Western literature than the extensive Chinese clinical use might imply, in part because much of that clinical use involves injectable danshen preparations and multi-herb formulas rather than standardized oral single-herb extracts. Formulators should calculate serving size against the assayed tanshinone percentage and be transparent that Western-standard oral dose-response data for isolated tanshinone-standardized extract is limited.

Analytical verification should specify total tanshinone content by HPLC with tanshinone IIA quantified separately, as tanshinone IIA is the most studied individual member and most of the mechanistic literature cited above concerns it specifically rather than the tanshinone mixture. Where a formulation relies on the herb’s full cardiovascular profile, salvianolic acid B content should be co-specified to confirm the hydrophilic fraction is present.

The most important safety consideration for this ingredient is a well-documented interaction: danshen has been repeatedly reported to potentiate the anticoagulant effect of warfarin, with case reports of elevated INR and bleeding events, a plausible interaction given tanshinone IIA’s documented platelet-aggregation-inhibiting activity. This warrants prominent caution language on any danshen-containing product regarding concurrent use with anticoagulant or antiplatelet medication. Standard caution regarding use before surgery is also appropriate given the antiplatelet mechanism.

---

Frequently Asked Questions — Tanshinones

Does a tanshinone percentage capture all of danshen's active compounds?
No, and this is a common and consequential misunderstanding. Danshen contains two distinct active fractions: the lipophilic tanshinones (tanshinone IIA, cryptotanshinone, and others) and a separate water-soluble phenolic fraction (salvianolic acids, danshensu). A tanshinone-standardized extract does not capture the salvianolic acid fraction, which contributes substantially to danshen's cardiovascular activity.

Can danshen be taken alongside blood thinners?
This requires serious caution. Danshen has been repeatedly reported to potentiate warfarin's anticoagulant effect, with case reports of elevated INR and bleeding, which is mechanistically plausible given tanshinone IIA's documented antiplatelet activity. Concurrent use with anticoagulant or antiplatelet medication warrants medical supervision.

How does tanshinone IIA act on the cardiovascular system?
Through multiple pathways rather than one. It inhibits LDL oxidation, monocyte adhesion to the endothelium, smooth muscle cell proliferation, macrophage cholesterol accumulation, pro-inflammatory cytokine expression, and platelet aggregation. More recent work also implicates anti-fibrotic activity via TGF-βR1 and pathways including Wnt, Notch, and ET-1.

Why is danshen's evidence base described as asymmetric?
Danshen is in extensive routine clinical use across China, generating a large Chinese-language clinical literature, but much of that evidence has not been validated under the trial-design standards typically required in Western regulatory contexts, and independent Western RCT data for tanshinone-standardized oral supplements specifically remains limited.

Related compounds: Tanshinone IIA, Rosmarinic Acid, Carnosic Acid, Salidroside

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery